Patients in Need of Levodopa Add-on Rate 3 Treatment Classes in Trial

Patients in Need of Levodopa Add-on Rate 3 Treatment Classes in Trial

315355

Patients in Need of Levodopa Add-on Rate 3 Treatment Classes in Trial

In treating Parkinson’s symptoms that aren’t being adequately controlled by levodopa, monoamine oxidase type B (MAO-B) inhibitors are better than catechol-O-methyltransferase (COMT) inhibitors, according to patient-reported assessments in a clinical trial. The real-world study found no difference in effectiveness between MAO-B — like COMT, a dopamine reuptake inhibitor — and dopamine agonists as an add-on therapy. Results were published in the study, “Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With…

You must be logged in to read/download the full post.